BiotechTube

filgrastim + exatecan mesylate

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Brain and Central Nervous System Tumors

Conditions

Brain and Central Nervous System Tumors, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific

Trial Timeline

Sep 1, 1999 → Apr 1, 2004

NCT ID
NCT00004212

About filgrastim + exatecan mesylate

filgrastim + exatecan mesylate is a phase 1 stage product being developed by Daiichi Sankyo for Brain and Central Nervous System Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT00004212. Target conditions include Brain and Central Nervous System Tumors, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific.

What happened to similar drugs?

5 of 18 similar drugs in Brain and Central Nervous System Tumors were approved

Approved (5) Terminated (2) Active (13)
✅ExenatideAstraZenecaApproved
✅RivastigmineNovartisApproved
✅Genotropin (PN-180,307) SomatropinPfizerApproved
✅Genotropin + PlaceboPfizerApproved
✅Dotarem® + Gadovist®/Gadavist®GuerbetApproved
🔄Nivolumab + TemozolomideOno PharmaceuticalPhase 3
🔄Nivolumab + TemozolomideOno PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00004212Phase 1Completed

Competing Products

20 competing products in Brain and Central Nervous System Tumors

See all competitors
ProductCompanyStageHype Score
Abemaciclib + Endocrine therapyEli LillyPhase 1/2
39
Duloxetine + Sugar pillEli LillyPhase 2
27
Neurosteroid enantiomerOragenicsPhase 2
32
Patritumab deruxtecanDaiichi SankyoPhase 2
27
Eribulin MesylateEisaiPhase 1
29
Pembrolizumab + LenvatinibEisaiPhase 2
42
Palonosetron (Aloxi) and DexamethasoneEisaiPhase 2
27
GLIADELEisaiPhase 2
35
Nivolumab + TemozolomideOno PharmaceuticalPhase 3
40
Nivolumab + TemozolomideOno PharmaceuticalPhase 3
40
Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastimEli LillyPhase 1
29
abemaciclib + abemaciclibEli LillyPhase 2
39
JNJ-17299425Johnson & JohnsonPhase 2
27
ABT-888AbbViePhase 1
29
Veliparib + PlaceboAbbViePhase 2
35
Iressa (Gefitinib)AstraZenecaPhase 2
27
Trastuzumab deruxtecanAstraZenecaPhase 2
42
ExenatideAstraZenecaApproved
43
AZD5213AstraZenecaPhase 1
29
VorinostatMerckPhase 1
29